Related Experiment Video
Updated: Jun 2, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Stereotactic radiosurgery for metastatic brain tumors
M Chamberlain1, P Kormanik, D Barba
1UNIV CALIF SAN DIEGO,DEPT NURSING,LA JOLLA,CA 92093. UNIV CALIF SAN DIEGO,DEPT SURG,LA JOLLA,CA 92093. UNIV CALIF SAN DIEGO,DEPT RADIOL,LA JOLLA,CA 92093.
International Journal of Oncology
|May 6, 2011
Summary
Stereotactic radiosurgery offers palliative benefits for brain metastases, especially as salvage therapy after whole brain radiotherapy. Further Phase III studies are needed to confirm the efficacy of adjuvant radiosurgery.
Area of Science:
- Neurosurgery
- Radiation Oncology
Background:
- Intracranial parenchymal metastases require effective treatment strategies.
- Whole brain radiotherapy (WBRT) is a standard treatment, but outcomes can be limited.
Purpose of the Study:
- To evaluate the efficacy and safety of stereotactic radiosurgery (SRS) for intracranial parenchymal metastases.
- To compare SRS as adjuvant therapy versus salvage therapy following WBRT.
Main Methods:
- Prospective Phase II study involving 50 patients with 1-3 brain metastases.
- Patients received SRS (median 20 Gy) either adjuvant to WBRT or as salvage therapy for disease progression.
- Outcomes assessed included survival and neurotoxicity.
Main Results:
- Median survival was 6.5 months for adjuvant SRS and 6.0 months for salvage SRS.
- 8% of patients developed symptomatic radiation necrosis; no immediate neurotoxicity was observed.
- Salvage SRS showed improved palliation compared to WBRT retreatment for progressing oligometastatic disease.
Conclusions:
- Stereotactic radiosurgery is a viable option for treating brain metastases.
- Salvage SRS may improve palliation in patients with disease progression after WBRT.
- Adjuvant SRS requires further investigation in Phase III trials to establish definitive benefit over WBRT alone.
